3rd Quarter - Report
THE MCMANUS GROUP for ROCHE DIAGNOSTICS
Firm
Client
Income
$40,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY GRACE DARCEY | — |
| JOHN MCMANUS | — |
| ABIGAIL SMITH | — |
| ALEX WHALEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.